Gene · 4017
Papers2,536
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 2,536
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Drug targets regulate systemic metabolism and provide new horizons to treat nonalcoholic steatohepatitis. | Metabol Open | 2024 | 38187470 | PubTator, text mining | PubMed |
| Dysregulation of extracellular matrix and Lysyl Oxidase in Ehlers-Danlos syndrome type IV skin fibroblasts. | Orphanet J Rare Dis | 2024 | 38183136 | PubTator, text mining | PubMed |
| Multiomics analysis of cultured mouse periodontal ligament cell-derived extracellular matrix. | Sci Rep | 2024 | 38172274 | PubTator, text mining | PubMed |
| Lipid metabolism-derived FAAH is a sensitive marker for the prognosis and immunotherapy of osteosarcoma patients. | Heliyon | 2024 | 38169921 | PubTator, text mining | PubMed |
| Impact of Molecular Dynamics of Polyrotaxanes on Chondrocytes in Double-Network Supramolecular Hydrogels under Physiological Thermomechanical Stimulation. | Biomacromolecules | 2024 | 38166194 | PubTator, text mining | PubMed |
| ITGB2-ICAM1 axis promotes liver metastasis in BAP1-mutated uveal melanoma with retained hypoxia and ECM signatures. | Cell Oncol (Dordr) | 2024 | 38150154 | PubTator, text mining | PubMed |
| Research progress of extracellular vesicles in the treatment of ovarian diseases (Review). | Exp Ther Med | 2024 | 38125352 | PubTator, text mining | PubMed |
| Pan-Cancer Analysis of the LOX Family Reveals that LOX Affects Tumor Prognosis by Affecting Immune Infiltration. | Crit Rev Eukaryot Gene Expr | 2024 | 38073445 | PubTator, text mining | PubMed |
| Implanting mechanically reprogrammed fibroblasts for aged tissue regeneration and wound healing. | Aging Cell | 2024 | 38010905 | PubTator, text mining | PubMed |
| Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer. | Clin Cancer Res | 2024 | 37882661 | PubTator, text mining | PubMed |
| Ribonucleotide reductase M2 (RRM2): Regulation, function and targeting strategy in human cancer. | Genes Dis | 2024 | 37588202 | PubTator, text mining | PubMed |
| Levoleucovorin inhibits LOXL2 (lysyl oxidase like-2) to control breast cancer proliferation: a repurposing approach. | J Biomol Struct Dyn | 2024 | 37340696 | PubTator, text mining | PubMed |
| Translational Studies Reveal the Divergent Effects of Simtuzumab Targeting LOXL2 in Idiopathic Pulmonary Fibrosis. | Fibrosis (Hong Kong) | 2023 | 38873180 | PubTator, text mining | PubMed |
| Emerging insights into keratin 7 roles in tumor progression and metastasis of cancers. | Front Oncol | 2023 | 38260844 | PubTator, text mining | PubMed |
| Doxorubicin-sensitive and -resistant colorectal cancer spheroid models: assessing tumor microenvironment features for therapeutic modulation. | Front Cell Dev Biol | 2023 | 38188017 | PubTator, text mining | PubMed |
| The categorizations of vasculogenic mimicry in clear cell renal cell carcinoma unveil inherent connections with clinical and immune features. | Front Pharmacol | 2023 | 38178861 | PubTator, text mining | PubMed |
| MASLD treatment-a shift in the paradigm is imminent. | Front Med (Lausanne) | 2023 | 38146424 | PubTator, text mining | PubMed |
| Copper in Gynecological Diseases. | Int J Mol Sci | 2023 | 38139406 | PubTator, text mining | PubMed |
| Insights into the Tumor Microenvironment-Components, Functions and Therapeutics. | Int J Mol Sci | 2023 | 38139365 | PubTator, text mining | PubMed |
| The Nexus of Inflammation-Induced Epithelial-Mesenchymal Transition and Lung Cancer Progression: A Roadmap to Pentacyclic Triterpenoid-Based Therapies. | Int J Mol Sci | 2023 | 38139154 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4017/papers?page=11